1. Home
  2. DCBO vs IMMX Comparison

DCBO vs IMMX Comparison

Compare DCBO & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$17.21

Market Cap

544.8M

Sector

N/A

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$9.00

Market Cap

528.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
IMMX
Founded
2016
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
544.8M
528.0M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
DCBO
IMMX
Price
$17.21
$9.00
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$32.00
$19.20
AVG Volume (30 Days)
230.0K
683.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.89
N/A
Revenue Next Year
$11.44
N/A
P/E Ratio
$22.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.39
$1.87
52 Week High
$33.42
$11.61

Technical Indicators

Market Signals
Indicator
DCBO
IMMX
Relative Strength Index (RSI) 44.79 43.88
Support Level $16.28 $8.15
Resistance Level $19.96 $10.53
Average True Range (ATR) 1.26 0.73
MACD -0.36 -0.04
Stochastic Oscillator 21.29 27.33

Price Performance

Historical Comparison
DCBO
IMMX

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: